Wednesday, July 8, 2026

Drug profile · INN

desmopressin acetate

desmopressin acetate (MINIRIN) is a vasopressin receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 8
Pipeline programs 8
News articles 0
Drug details — desmopressin acetate
US status
approved
Class
Route
ORAL
Patents
8
Programs
8
Data quality
0.89

Quick answer

desmopressin acetate (MINIRIN) is a vasopressin receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.

Key facts

INN desmopressin acetate
Brand MINIRIN
Mechanism Vasopressin receptor agonist
Target Vasopressin receptor
Route ORAL
Formulation INJECTABLE

Mechanism of action

Vasopressin receptor agonist

Primary target: Vasopressin receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 2021/ABM/01/00010 Phase 3 · Bial Portela & · Rare and ultra-rare glomerulonephritis
  2. APHP220676 Phase 3 · PARItec · Severe hyponatremia and a high risk of rapid SNa overcorrect
  3. Nomlabofusp, Placebo to Nomlabofusp Phase 3 · Larimar Therapeutics · Friedreich’s ataxia is the most common inherited ataxia in h
  4. 22534 Phase 1 · Bayer · Onchocerciasis (river blindness): is an infectious disease c
  5. DBP-053-01 Phase 1 · Anaxis Pharma · Glioblastoma
  6. Desmopressin Acetate 0.2 mg Tablets Phase 1 · Teva Pharma · Healthy
  7. Desmopressin Approved · First People's Hospital · Patients Undergoing Endoscopic Sinus Surgery
  8. OCT Unknown · Cardiff Oncology · AMD

Related & competitor drugs

  1. vasopressin Vasopressin receptor agonist
  2. lypressin Vasopressin receptor agonist
  1. US 12390509

    Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12351611

    Molecules for organelle-specific protein delivery

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12091437

    Molecules for organelle-specific protein delivery

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11976100

    Methods for treating myelin associated diseases and mitochondria associated diseases

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11891420

    Molecules for organelle-specific protein delivery

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. CA 2723411

    PROCEDE

    Expires Wed Nov 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. TW 200942531

    Crystal forms of a nitrocatechol

    Expires Thu Oct 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. WO 2009084970

    3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE

    Expires Wed Jul 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is desmopressin acetate?

desmopressin acetate (MINIRIN) is a vasopressin receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.

What is the brand name for desmopressin acetate?

MINIRIN is a marketed brand name for desmopressin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of desmopressin acetate?

desmopressin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.